Non surgical treatment for Keratoconus – latest advancement with eye drops
Non surgical treatment for Keratoconus – latest advancement with eye drops
Donor tissue that had been treated with IVMED-80 showed better stress-strain curves, Dr. Ambati said. In vivo rabbit studies with IVMED-80 showed increased ysyl oxidase activity, which he noted as biomechanical evidence of increased crosslinking. There have been no toxic or adverse events. Currently, a Phase 1/2a clinical trial in Mexico is taking place with 36 keratoconus or post-LASIK ectasia patients who take two drops a day of either vehicle or IVMED-80. The primary end-point is reduction of kmax and kmean at 6 months with a secondary endpoint of biomechanical stiffness. At 1 month, 0.6 D of flattening seen at 1 year with the Dresden crosslinking protocol.
A pharmacologic method of flattening the cornea, Dr. Ambati and should, perhaps, take more of Dr. Ambati’s focus. From a financial/investment standpoint, Dr. Link said that this would be a relatively expensive project to do properly and the first quality investment would need to see detailed planning out to FDA approval.
Categories:
https://bestcataracthospitalinmumbai.blogspot.com/2019/05/benefits-risks-of-cataract-surgery-in.html
Comments
Post a Comment